ONXX – Stripping out the effect of currency, the Nexavar year-over-year growth rate in 3Q08 was 63% (vs 59% as reported in euros). Only 26% of 3Q08 Nexavar sales were in the US, where the YoY growth rate net of currency effects was 19%. Why is the sales uptake so much slower in the US than in Europe?